Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Protagonist Therapeutics

Explore full profile

Develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies

Newark, United StatesFounded 2006Biotech & Life Sciences
Valuation $8.39B Market cap · 2026
Revenue $46M Latest reported FY
Total funding $50–100M Disclosed equity funding

About Protagonist Therapeutics

Protagonist Inc. is a clinical-stage biopharmaceutical company that focuses on peptide drug discovery and development. Their mission is to improve patients' lives by addressing areas of unmet need in both rare and prevalent diseases where current treatments are either limited or inadequate. They operate in the healthcare and pharmaceutical market, specifically in the area of drug discovery and development.

Read full description

Their business model revolves around the discovery, development, and commercialization of peptide-based drugs. They conduct clinical trials to test the efficacy and safety of these drugs, with the ultimate goal of bringing them to market. Once a drug is approved for use, they generate revenue through its sale.

Protagonist Inc. is also committed to health equity and improving access to medicines. They ensure diverse representation in their clinical studies by actively seeking patients from various locations, age groups, and backgrounds. This includes a focus on including aging populations who are often left out of clinical studies.

In addition to their commitment to diverse patient representation, Protagonist Inc. also values diversity and inclusion within their workplace. They believe that a diverse and inclusive corporate culture is critical to their long-term success and innovation.

Source: Dealroom company data

At a glance

Founded
2006
Headquarters
Newark, United States
Listing
IPO 2016
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Series A6 investors entered at this stage

  • Starfish Ventures
  • Lilly Ventures
  • QIC BioVentures
  • Johnson & Johnson Development Corporation
  • Inbio Ventures
  • Pharmstandard

Series B and later6 investors entered at this stage

Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States92.7%
🇦🇺 Australia7.3%
2 countries shown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States90%
🇮🇳 India5.5%
🇯🇵 Japan1.8%
🇬🇧 United Kingdom1.8%
Top 4 markets shown

Patents

Estimated portfolio value
$63M

48 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Protagonist Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Protagonist Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.